TOP STORY
The American Academy of Pediatrics (AAP) has published a policy statement to provide pediatricians with recommendations for assessing and treating Clostridium difficile infections (CDI) in children. » More |
Continuing Education
Welcome to the fifth activity in our CPE series: Medication Therapy Management (MTM) in Patients with Diabetes, which has been designed for pharmacists who take care of patients with diabetes. You can earn up to 14 credits from September 2012-March 2013 with 7 monthly knowledge-based activities. The January activity covers macrovascular and microvascular complications of diabetes mellitus.
To read and print the article with TEST QUESTIONS, click here. To proceed to the online exams and earn up to 2 CPE credits, click here to login.
Announcement: Welcome to the new user registration process. This new process requires all pharmacists and pharmacy technicians to provide
or update their NABP e-Profile ID in order to electronically keep track of CPE credits from ACPE-accredited providers. If you have not done so, you can obtain your NABP e-Profile ID now at
www.MyCPEmonitor.net. This profile will enable you to have one login
for all the NABP programs and services you will need throughout your career.
|
TODAY'S HEADLINES
To help prevent opioid abuse, New York City hospitals will be limiting opioid prescriptions dispensed from their emergency departments to a three-day supply, will not be prescribing long-acting opioids, and will not be refilling lost, stolen, or destroyed prescriptions, according to new voluntary emergency room guidelines that were made available on Jan. 10. » More |
|
FDA’s recent approval of crofelemer (Fulyzaq, Salix Pharmaceuticals, under license from Napo Pharmaceuticals), 125-mg delayed-release tablets, the first antidiarrheal drug for HIV/AIDS patients taking antiretroviral therapy (ART), is a significant step forward in addressing the unmet medical need of people with HIV/AIDS on ART who experience noninfectious diarrhea, which often can lead to reduced treatment compliance.
» More |
|
In a drug safety communication, FDA has recommended that the bedtime dose of zolpidem, for the treatment of insomnia, be lowered because new data show that blood levels in some patients may be high enough the morning after use to impair activities that require alertness, including driving. » More
|
|
TAKE OUR SURVEY
- Yes
- No
Click Here to let us know.
|
|
|
Like
Tweet
